Data / Drug companies / Omeprazole magnesium
Omeprazole magnesium: 21 companies and 27 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Omeprazole magnesium is listed in the FDA National Drug Code Directory by 21 companies, with 27 products in commercial distribution. 23 of the products (85.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, delayed release; tablet, delayed release; granule, delayed release, and the newest product started marketing on September 1, 2026.
The request: Get every company that lists omeprazole magnesium in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 21
- Products
- 27
- Generic (ANDA) products
- 23 (85.2%)
- Application numbers
- 6
- Routes
- Oral
- Brand names
- Prilosec Otc, Omeprazole, Omeprazole, Prilosec, Equate Omeprazole, Basic Care Omeprazole, Acid Reducer
- openFDA record search
- api.fda.gov
Companies that list omeprazole magnesium
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Walgreen Company | 3 | capsule, delayed release | Generic drugs (ANDA) | April 9, 2024 |
| Covis Pharma US, Inc | 2 | granule, delayed release | New drug applications (NDA) | August 25, 2017 |
| Safeway | 2 | capsule, delayed release | Generic drugs (ANDA) | June 3, 2024 |
| The Procter & Gamble Manufacturing Company | 2 | tablet, delayed release | Generic drugs (ANDA) | September 1, 2025 |
| The Procter & Gamble Manufacturing Company | 2 | tablet, delayed release | New drug applications (NDA) | August 15, 2012 |
| Amazon.com Services LLC | 1 | capsule, delayed release | Generic drugs (ANDA) | February 22, 2023 |
| CVS Pharmacy | 1 | capsule, delayed release | Generic drugs (ANDA) | November 1, 2011 |
| CVS Woonsocket Prescription Center, Incorporated | 1 | capsule, delayed release | Generic drugs (ANDA) | April 1, 2025 |
| Cardinal Health 110, LLC. DBA Leader | 1 | capsule, delayed release | Generic drugs (ANDA) | March 7, 2017 |
| Chain Drug Consortium, LLC | 1 | capsule, delayed release | Generic drugs (ANDA) | January 1, 2016 |
| Chain Drug Marketing Association | 1 | capsule, delayed release | Generic drugs (ANDA) | January 1, 2016 |
| Chain Drug Marketing Association, Inc. | 1 | capsule, delayed release | Generic drugs (ANDA) | January 1, 2016 |
| Discount Drug Mart | 1 | capsule, delayed release | Generic drugs (ANDA) | November 18, 2016 |
| Dr. Reddy's Laboratories Inc. | 1 | capsule, delayed release | Generic drugs (ANDA) | December 26, 2018 |
| Dr. Reddy's Laboratories Limited | 1 | capsule, delayed release | Generic drugs (ANDA) | March 1, 2010 |
| Geri-Care Pharmaceuticals, Corp | 1 | capsule, delayed release | Generic drugs (ANDA) | April 1, 2013 |
| H E B | 1 | capsule, delayed release | Generic drugs (ANDA) | January 1, 2016 |
| Meijer, Inc. | 1 | capsule, delayed release | Generic drugs (ANDA) | August 24, 2023 |
| Target Corporation | 1 | capsule, delayed release | Generic drugs (ANDA) | July 21, 2018 |
| Walmart Inc. | 1 | capsule, delayed release | Generic drugs (ANDA) | November 30, 2022 |
| Yyba Corp | 1 | capsule, delayed release | Generic drugs (ANDA) | September 1, 2026 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule, delayed release | 21 | 77.8% |
| Tablet, delayed release | 4 | 14.8% |
| Granule, delayed release | 2 | 7.4% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 23 | 85.2% |
| New drug applications (NDA) | 4 | 14.8% |
Pharmacologic classes
| Class | Products |
|---|---|
| Proton Pump Inhibitor | 27 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.